Our study of ERV expression in an immune competent genetically engineered mouse model of prostate cancer revealed that Trim28 deletion in NPp53 prostate tumors in both hormonally intact and castrated mice resulted in increased expression of ERVs at numerous loci. This evidence concerns the gene TRIM28 and prostate carcinoma.